Phaseline

Targets › CD56

CD56: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: the race on CD56, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing BiotechEB-DART-NK01
Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2)
DLL3, CD56, GD2Phase 1Small Cell Lung Cancer (SCLC)Feb 2027

Conditions

Small Cell Lung Cancer (SCLC) (2)

Modalities

protein or peptide (1)

Companies

Beijing Biotech (1)

Related targets

DLL3 (1) GD2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.